US hospitals use predictive AI tools, but many use biased data: Most AI models make recommendations based on homogenous data samples, which could actually harm many patients. But more regulatory oversight of healthcare AI isn’t guaranteed to happen in the near term.

Gen Z struggles to manage health and wellness: They understand the importance of taking health into their own hands but fail to deliver good results. We explore how healthcare marketers, providers, and insurers can arm this generation with the necessary support.

Google DeepMind expects AI-designed drug trials to start this year: While the jury is out on how effective the tech is at accelerating drug discovery, that hasn’t stopped pharma companies from pursuing tie-ups with the firm to do just that.

Sanofi’s Opella secures FDA nod to pursue OTC Cialis study: If Cialis’ shift from a prescription drug to over-the-counter product comes to fruition, both consumers and D2C retailers could benefit.

CMS unveils list of drugs for the next round of Medicare price negotiations: Drugmakers’ efforts to win over the Trump administration could amend the process in their favor—up to a certain point.

Cancer patients are getting younger: Healthcare marketers can make preventive screening guidance less complicated for patients. We explore how.

Trump signs order for the US to leave the World Health Organization: The decision could turn into a public health nightmare for the US, while also impeding health initiatives worldwide.

Consumers want AI that’s vetted by doctors: They believe the tech can improve their experience, but only if it’s been responsibly implemented and its conclusions verified by a human clinician.

What a TikTok ban means for healthcare and pharma: Health influencers, marketers, and patients have all gravitated toward TikTok in recent years. We examine the implications of a ban on each.

UnitedHealth Group’s shares fall after mixed Q4 earnings: While the healthcare titan will have to contend with potential changes to how its pharmacy benefit manager does business, its reaffirmed outlook for 2025 suggests it’s not too concerned.

Investor enthusiasm, AI tie-ups stand out at JP Morgan Healthcare Conference: We expect future investment activity to be driven by the AI arms race taking place across the healthcare and pharma industries.

Drugmakers will push Trump to delay Medicare price negotiations: We believe the drug price negotiation program is well-intended given how much Medicare and US consumers pay for certain medications. While a program reversal is unlikely, we’ll find out soon what the Trump administration thinks.

Doctors’ ethics ratings slip: We explore what’s driving the decline in this new data, and examine how trust in physicians can be rebuilt.

Hippocratic AI rolls out AI agent app store: Licensed US clinicians can use the store to create “AI agents” that carry out certain clinical tasks, helping to augment their work and free up time for direct patient care.

Could Trump’s second term include a ban on D2C pharma ads? We examine the likelihood of a ban and explore what more oversight of drug ads on TV means for pharma marketers.

Walgreens’ Q1 earnings report sends shares soaring: For its Q1 turnaround to translate into long-term success, the company will need to foster an improved experience that convinces customers to actually step foot in its stores.

New rule removes medical debt from credit reports: While this will help in terms of approval and interest rates for loans, relief won’t be felt until health systems stop aggressively chasing down patients’ unpaid bills.

Meta’s healthcare ad changes go into effect: Healthcare advertisers will need to get creative and experiment with different approaches to effectively reach their target audiences in light of the changes.

Transcarent to acquire Accolade for $621M: The deal could lower costs for employer and health plan customers. It’s also an indicator that more digital health M&As will take place in 2025.

Pharma is forecast for positive momentum in 2025: But increases in drug approvals and product sales are no guarantee as the US transitions to a new administration.